Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Asitha Abeywardane

Hidenori Takahashi

Lana Louise Smith Keenan

Qiang Zhang

Thomas Martin Kirrane, Jr

Michael Robert Turner

Michael Jason Burke

Steven John Taylor

Hossein Razavi

Robert Sibley

Roger John Snow

Matthew Russell Netherton

Anil Kumar Padyana

Steven Richard Brunette

Qing Zhang

Renee M Zindell

Ming-Hong Hao

Tina Marie Morwick

Erick Richard Roush Young

Donghong Amy Gao

Alexander Heim-Riether

Chuk Chui Man

Yang Yu

John Broadwater

Daniel R Goldberg

Derek Cogan

Yancey David Ward

Suresh R Kapadia

Ronald John Sorcek

Yunlong Zhang

Zhaoming Xiong

Stephane De Lombaert

Daniel Richard Marshall

Peter Allen Nemoto

Michel Jose Emmanuel

Ho Yin Lo

Jiang-Ping Wu

Brian Nicholas Cook

Sonia Rodriguez

Craig Andrew Miller

Jin Mi Kim

Ingo Andreas Mugge

Xin Guo

Kevin Chungeng Qian

Anjan Saha

Denise Andersen

Philip Dean Ramsden

Michael J Burke

Neil Alexander Farrow

Lana Louise Smith-Keenan

Younggi Choi

Bennett Farmer

John Alan Broadwater

Michael Jason Bruke

Donghong A Gao

The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Inhibitors of leukotriene production

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, A, Land B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Ris defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTAH) and treating LTAH related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

Benzimidazolone chymase inhibitors

The present invention relates to compounds of formula (I): wherein Rto R, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Benzodioxane inhibitors of leukotriene production

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.  Also disclosed are pharmaceutical compositions, methods of using and making the same.

Chymase inhibitors

Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I. 

Heteroaryl substituted indole compounds useful as MMP-13 inhibitors

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R, R, R. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10. 

2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10

Heterocyclic compounds which are inhibitors of Mitrogen-Activated Protein Kinase-Activated Protein Kinase-2 (MAPKAP-K2) as described, in addition to their use in the treatment of cytokine mediated diseases.

Anti-cytokine heterocyclic compounds

Growing community of inventors

Danbury, CT, United States of America

Asitha Abeywardane